Khashayar Dashtipour, MD, PhD, director of the Division of Movement Disorders at Loma Linda University and paid consultant of Acadia Pharmaceuticals Inc., shares insights on balancing the treatment of motor and non-motor symptoms, and the importance of timely intervention for Parkinson’s disease psychosis.
Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.
Jason Freeman, MD, MBA, and Gina Mavrikis Cox, PhD, discuss a presentation from CMSC 2023 on the role of serum biomarkers in multiple sclerosis management. Sponsored by Novartis.
Sponsored by Cerevel Therapeutics
The results of a phase 4 study demonstrate the efficacy of APOKYN® (apomorphine hydrochloride injection) treatment.
This year, Teva is celebrating the 25th anniversary of the FDA approval of COPAXONE® (glatiramer acetate injection), but the story goes back much further. Hear what some of Teva's most prominent R&D leaders have to say about the history and origins of the treatment.
